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The control of ticks with vaccines is of global interest. Experimental vaccines incorporate new technolo-
gies as soon as they are available. Historically, the main vaccine studies have focused on the one-host cat-
tle tick Rhipicephalus microplus, and efﬁcacy evaluations have been standardised for this tick species. On
the other hand, evaluations of vaccine candidates for three-host ticks are being done somewhat arbitrar-
ily and thus comparisons within the current literature on the efﬁcacy of vaccines, as well as other meth-
ods of control, are difﬁcult. We herein provide a formula for the evaluation of efﬁcacy of a vaccine
designed against three-host ticks that incorporates the whole life cycle of the tick.
 2015 The Authors. Published by Elsevier Ltd. on behalf of Australian Society for Parasitology Inc. This is
an open access article under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/4.0/).The calculation of tick vaccine efﬁcacy is used to report the per-
centage of immunoprotection of a product against the parasite.
This calculation has been applied around the world overwhelm-
ingly for products designed against the cattle tick, Rhipicephalus
microplus (and Rhipicephalus australis). In the ﬁrst report of vaccine
efﬁcacy against the cattle tick, Wong and Opdebeeck (1989) used a
formula containing only three parameters: total number of
detached adults, oviposition of adults and egg mass weight. Eight
years later, Canales et al. (1997) calculated for the ﬁrst time the
current standard test for vaccine efﬁcacy against ticks. In fact, this
formula was used to test the efﬁcacy of the commercial vaccine
Gavac™ (Heber Biotec S.A., Havana, Cuba), developed to control
the R. microplus and Rhipicephalus annulatus populations (Fragoso
et al., 1998). This formula calculates the efﬁcacy (E%) based on
three variables: number of detached engorged adults (CRT), egg
mass weight (CRO) and fertility of eggs (CRF) as follows (Canales
et al., 1997; Andreotti, 2007; Miller et al., 2012):
E% ¼ 100  ½1 ðCRT  CRO  CRFÞ:At the same time, control of the three-host tick species, such as
Rhipicephalus sanguineus, Amblyomma variegatum and Ixodes scapu-
laris, is also on the research agenda but a standard formula has not
yet been established. In the last few years it has been proposed to
validate vaccine efﬁcacy by correlating antibody titers in individual
animals with some of the tick parameters, which we included in
the formula discussed below (Szabó and Bechara, 1997; Almazán
et al., 2003, 2005; Trimnell et al., 2005; Pérez-Pérez et al., 2010;
Anisuzzaman et al., 2012). Almazán et al. (2005) calculated the efﬁ-
cacy of an antigen against the three-host tick I. scapularis, based
only on its effect against larvae. Trimnell et al. (2005) tested a
cement antigen as a vaccine in guinea pigs against R. sanguineus
and in hamsters and rabbits against Ixodes ricinus, however, in all
cases the ﬁnal efﬁcacy was not calculated and only some life cycle
parameters were compared using ANOVA. Pérez-Pérez et al. (2010)
inoculated dogs with Bm86 antigen (Hebercani, Heber Biotec) to
evaluate its efﬁcacy against R. sanguineus; nevertheless they only
compared some parameters with means comparison using a
Student’s t-test. Similar analysis has been done previously when
R. sanguineus gut extract was tested as a vaccine in guinea pigs
against this tick (Szabó and Bechara, 1997). The work of
Rodríguez-Mallon et al. (2012) was the only known report on vac-
cine efﬁcacy against a three-host tick which considered the
cumulative effect of the product against larvae, nymphs and adult
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ery and viability of engorged larvae in only one parameter, disre-
garded the number of engorged nymphs that molt to adults, and
used twice the number of detached engorged females in their
formula. Thus, the vaccine efﬁcacy was over-estimated. The ﬁnal
formula reported was:
Eð%Þ ¼ 100  ½1 ðVL  RN  RA  VA  OA  FEÞ
where
VL is the effect of each immunogen on larval viability.
RN is the effect of each immunogen on nymph yield.
RA is the effect of each immunogen on adult yield.
VA is the effect of each immunogen on adult viability.
OA is the effect of each immunogen on oviposition of females.
FE is the effect of each immunogen on fertility of eggs.
Here we propose an alternative formula of vaccine efﬁcacy for
three-host ticks, which cumulatively calculates the values of each
instar, avoiding an over-estimated result, and calculates the ability
of each tick instar to complete its blood meal as well as to molt to
the next stage. The ability of adult females to lay eggs and larvae
hatchability were also considered, resulting in a ﬁnal percentage
that includes values of larvae, nymphs and adults/weight of mass
of eggs of three-host ticks. Thus, we propose to separate the larvae
parameter into two and add one parameter for nymphs in relation
to the formula cited above. For larvae, we considered separately
the effect on recovery, which counts the total number of engorged
larvae from the vaccinated group in relation to the control group.
For nymphs, we included their viability, in other words, the total
engorged nymphs that are able to molt to adults from the vacci-
nated group compared with the control group.
The formula cited by Rodríguez-Mallon et al. (2012) includes
four parameters for adults, but two of those cause an over-
estimation of the ﬁnal value since they calculate values for the
same condition. The VA variable calculates the viability of an
engorged female to lay eggs by counting howmany females within
the recovered total have started oviposition. On the other hand, the
OA variable shows the same when the average mass weight of eggs
per female recovered is calculated. All eggs came from females that
had already started oviposition, so when the total mass of eggs was
divided by the total number of recovered females, the same
parameter that had previously been calculated is included, which
was the number of engorged females that had started oviposition.
We propose including only three parameters for adults in the for-
mula, one being the parameter that calculates both the effects of
the reduction in females able to lay eggs and the average weight
of eggs laid by each engorged female. Each value was determined
by the ratio between the average values of the vaccinated group
and the control group. All cross-linked parameters are multiplied,
providing the ﬁnal percentage of efﬁcacy. The ﬁnal value is sub-
tracted from one and multiplied by 100, to obtain the overall
reduction, as a percentage, caused by the vaccine in tick yield
throughout the whole of the tick life cycle. Thus, we can use the
effects on both the host and environment to determine the effect
of the vaccine on the parasite burden.
The ﬁnal formula is:
Eð%Þ ¼ 100  ½1 ðRL  VL  RN  VN  RA  OA  FEÞ
where
E is the vaccine efﬁcacy percentage.
RL is the effect on recovery of engorged larvae. This variable is
calculated by the ratio between engorged larvae recovered fromthe vaccinated (rlv) group in relation to the control group (rlc).
RL = (rlv/rlc).
VL is the effect on the viability of engorged larvae. This variable
is calculated based on the ratio of the total number of engorged
larvae recovered that molted to nymphs from the vaccinated
(vlv) group compared with the control group (vlc). VL = (vlv/
vlc).
RN is the effect on recovery of engorged nymphs. This variable
is calculated as the ratio between engorged nymphs recovered
from the vaccinated (rnv) group in relation to the control group
(rnc). RN = (rnv/rnc).
VN is the effect on the viability of engorged nymphs. This vari-
able is calculated based on the ratio of the total number of
engorged nymphs recovered that molted to adults from the vac-
cinated (vnv) group compared with the control group (vnc).
VN = (vnv/vnc).
RA is the effect on recovery of engorged adults. This variable is
calculated as the ratio between engorged adults recovered from
the vaccinated (rav) group compared with the control group
(rac). RA = (rav/rac).
OA is the effect on oviposition of adult females. This variable is
calculated based on the average weight of egg mass laid by
engorged adult females recovered from the vaccinated (oav)
group compared with the control group (oac). OA = (oav/oac).
FE is the effect on egg fertility. This variable is calculated based
on the ratio between the hatchability, as a percentage, of larvae
from eggs laid by engorged adults recovered from the vacci-
nated group (fev) compared with the control group (fec).
FE = (fev/fec).
Including all proposed parameters in the new formula, and not
only those that are statistically signiﬁcantly different between
treated and control groups, may dilute antagonistic effects of a vac-
cine or a drug on speciﬁc parameters of ticks. However, for those
who will use a vaccine against ticks, the described efﬁcacy should
include the overall effect on the parasite. Also, additive effects on
various parameters throughout the tick life cycle should be consid-
ered. In this regard, it is possible to suppose that the sum of small,
non-signiﬁcant negative effects of several of the parameters will
result in a ﬁnal, signiﬁcant negative effect on the efﬁcacy for tick
control. Last but not least, apart from the proposed formula, it is
always important to evaluate the effect of a vaccine on speciﬁc
parameters. Such an approach will be important to better under-
stand the mode of action of the product.
Although it was developed to calculate efﬁcacy under lab-
oratory conditions, it is also possible to use this formula in the
ﬁeld, however, the data for all tick stages would likely be more
time-consuming to collect than under laboratory conditions
because some developmental stages might not feed on hosts at
the same time. Using Amblyomma cajennense as an example where
the life cycle usually takes 1 year to complete (Guglielmone et al.,
1990), the treatment of hosts should be planned to provide protec-
tion for at least 1 year and tick collection should aimed to recover
all tick stages at the end of the trial, providing the researcher with
all of the data that the formula requires. Another scenario that
could improve the accuracy of the formula is to use the same ticks
from larvae until oviposition of eggs, under laboratory conditions.
This way, the real cumulative effects will be preserved, because
each tick stage would load the vaccine/substance effect from the
previous stage.
In conclusion, it is possible to use this formula under any condi-
tions as the required parameters can be collected and measured.
Therefore, we suggest this formula as useful for vaccine evaluation
or substance efﬁcacy in three-host ticks.
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